RS60424B1 - Modulatori nukleusnog transporta i njihove upotrebe - Google Patents
Modulatori nukleusnog transporta i njihove upotrebeInfo
- Publication number
- RS60424B1 RS60424B1 RS20200639A RSP20200639A RS60424B1 RS 60424 B1 RS60424 B1 RS 60424B1 RS 20200639 A RS20200639 A RS 20200639A RS P20200639 A RSP20200639 A RS P20200639A RS 60424 B1 RS60424 B1 RS 60424B1
- Authority
- RS
- Serbia
- Prior art keywords
- nuclear transport
- transport modulators
- modulators
- nuclear
- transport
- Prior art date
Links
- 230000025308 nuclear transport Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644802P | 2012-05-09 | 2012-05-09 | |
| US201361798188P | 2013-03-15 | 2013-03-15 | |
| EP18164757.9A EP3404027B1 (en) | 2012-05-09 | 2013-05-09 | Nuclear transport modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60424B1 true RS60424B1 (sr) | 2020-07-31 |
Family
ID=49448240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20200639A RS60424B1 (sr) | 2012-05-09 | 2013-05-09 | Modulatori nukleusnog transporta i njihove upotrebe |
| RS20181360A RS58058B1 (sr) | 2012-05-09 | 2013-05-09 | Modulatori nukleusnog transporta i njihove upotrebe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20181360A RS58058B1 (sr) | 2012-05-09 | 2013-05-09 | Modulatori nukleusnog transporta i njihove upotrebe |
Country Status (32)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2791914C (en) | 2010-03-05 | 2019-01-15 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| AU2012207565B2 (en) | 2011-01-17 | 2016-04-07 | Karyopharm Therapeutics Inc. | Olefin containing nuclear transport modulators and uses thereof |
| PE20141003A1 (es) | 2011-07-29 | 2014-09-02 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear y usos de los mismos |
| AR087342A1 (es) | 2011-07-29 | 2014-03-19 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear que contienen hidrazida y sus usos |
| NZ702663A (en) | 2012-05-09 | 2017-03-31 | Karyopharm Therapeutics Inc | Nuclear transport modulators and uses thereof |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| LT2945939T (lt) | 2013-01-15 | 2020-07-27 | Incyte Holdings Corporation | Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai |
| US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
| MX365939B (es) | 2013-06-21 | 2019-06-19 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear y usos de los mismos. |
| WO2014205393A1 (en) * | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物 |
| KR102391334B1 (ko) * | 2014-05-13 | 2022-04-26 | 큐에스에이 글로벌 인크. | 향상된 이리듐 감마 방사 선원을 위한 장치 및 방법 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| EP3180331B1 (en) | 2014-08-15 | 2022-06-08 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
| KR101734529B1 (ko) | 2015-05-08 | 2017-05-11 | 건국대학교 산학협력단 | 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물 |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| CA2996513A1 (en) * | 2015-08-25 | 2018-03-02 | President And Fellows Of Harvard College | Methods and compositions relating to the diagnosis and treatment of cancer |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| MA43530A (fr) * | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2017151587A1 (en) * | 2016-02-29 | 2017-09-08 | Ohio State Innovation Foundation | Aza-peptide aldehydes and ketones |
| WO2017161172A1 (en) * | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Methods of modulating keap1 |
| WO2017190087A1 (en) | 2016-04-30 | 2017-11-02 | Envision Diagnostics, Inc. | Medical devices, systems, and methods for performing eye exams and eye tracking |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| KR20230110828A (ko) | 2018-01-10 | 2023-07-25 | 엑스더블유파마 리미티드 | 케타민의 전구약물, 및 이의 조성물 및 용도 |
| WO2019232724A1 (en) | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
| WO2020092965A1 (en) * | 2018-11-01 | 2020-05-07 | Karyopharm Therapeutics Inc. | E2f1 as a biomarker for treatments using xpo1 inhibitors |
| WO2020117772A1 (en) | 2018-12-06 | 2020-06-11 | Biogen Ma Inc. | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
| CN111606890A (zh) * | 2019-02-26 | 2020-09-01 | 微境生物医药科技(上海)有限公司 | 含丙烯酰基的核转运调节剂及其用途 |
| CN109928939A (zh) * | 2019-02-27 | 2019-06-25 | 上海卡洛化学有限公司 | 一种2,2,6,6-四甲基吗啉的制备方法 |
| BR112021021706A2 (pt) * | 2019-05-01 | 2022-04-19 | Karyopharm Therapeutics Inc | Processo para preparar inibidores de xpo1 e intermediários para uso na preparação de inibidores de xp01 |
| CN111145135B (zh) * | 2019-12-30 | 2021-08-10 | 腾讯科技（深圳）有限公司 | 一种图像去扰处理方法、装置、设备及存储介质 |
| WO2022209477A1 (ja) | 2021-04-01 | 2022-10-06 | アルプスアルパイン株式会社 | 操作検出装置 |
| AU2022326513B2 (en) | 2021-08-13 | 2025-07-24 | XWPharma Ltd. | Pharmaceutical compositions and oral dosage forms of ketamine derivatives |
| WO2023172855A2 (en) * | 2022-03-07 | 2023-09-14 | Kaohsiung Medical University | Methods for treating hepatitis b virus infection |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017398A (en) | 1911-01-16 | 1912-02-13 | John E Folsom | Telegraph-key. |
| CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
| KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| US5468353A (en) | 1994-05-05 | 1995-11-21 | Minnesota Mining And Manufacturing Company | Mist suppressant for solvent extraction metal electrowinning |
| CA2205998C (en) | 1994-11-23 | 2002-07-16 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| EP0858457A1 (de) | 1995-10-20 | 1998-08-19 | Dr. Karl Thomae GmbH | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
| JP4064462B2 (ja) | 1996-04-04 | 2008-03-19 | 塩野義製薬株式会社 | セフェム化合物及び該化合物を含有する医薬 |
| ATE244219T1 (de) | 1996-04-25 | 2003-07-15 | Nissan Chemical Ind Ltd | Ethylenderivate und pestizide |
| JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| WO1999050264A1 (fr) | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Derives de quinazoline |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| CA2423868C (en) * | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| JP3608050B2 (ja) | 2001-07-24 | 2005-01-05 | トヨタ自動車株式会社 | ロールオーバ判別装置 |
| US7595343B2 (en) | 2001-09-14 | 2009-09-29 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2004037248A2 (en) | 2002-10-24 | 2004-05-06 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| NZ540381A (en) | 2002-11-01 | 2007-11-30 | Takeda Pharmaceutical | 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy |
| JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| AU2003291403A1 (en) | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| CA2512886A1 (en) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| KR101128065B1 (ko) | 2004-05-26 | 2012-04-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물 |
| CA2575039A1 (en) | 2004-08-11 | 2006-02-16 | Kyorin Pharmaceutical Co., Ltd. | Novel cyclic amino benzoic acid derivative |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| WO2006088246A1 (ja) | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Ｇｐｒ３４受容体機能調節剤 |
| PL1954684T3 (pl) | 2005-11-15 | 2014-10-31 | Otsuka Pharma Co Ltd | Związek oksazolowy i kompozycja farmaceutyczna |
| JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
| KR101464651B1 (ko) | 2006-03-09 | 2014-11-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 다환식 신나미드 유도체 |
| KR101495611B1 (ko) | 2006-04-07 | 2015-02-25 | 메틸진 인코포레이티드 | 히스톤 데아세틸라아제의 억제제 |
| AU2007239283B2 (en) | 2006-04-18 | 2013-02-07 | Nippon Chemiphar Co., Ltd. | Activating agent for peroxisome proliferator activated receptor delta |
| KR101130380B1 (ko) | 2006-06-13 | 2012-04-23 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도 |
| CN100503571C (zh) | 2006-07-12 | 2009-06-24 | 中国药科大学 | 四氢异喹啉类衍生物、其制备方法及其医药用途 |
| WO2008013414A1 (en) | 2006-07-27 | 2008-01-31 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| WO2008029825A1 (fr) | 2006-09-05 | 2008-03-13 | Kyowa Hakko Kirin Co., Ltd. | Dérivé d'imidazole |
| EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| JP2010519337A (ja) | 2007-02-26 | 2010-06-03 | コーサン バイオサイエンシーズ， インコーポレイテッド | カルバメート化合物 |
| EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
| US20100179203A1 (en) * | 2007-07-04 | 2010-07-15 | Antonio Nardi | Novel pyrazole derivatives useful as potassium channel modulators |
| EP2451280A4 (en) | 2009-07-09 | 2012-12-26 | Crescendo Therapeutics Llc | METHOD FOR WOUND HEALING AND SCALING MODULATION |
| WO2011069039A1 (en) * | 2009-12-04 | 2011-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
| CA2791914C (en) | 2010-03-05 | 2019-01-15 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| AU2012207565B2 (en) | 2011-01-17 | 2016-04-07 | Karyopharm Therapeutics Inc. | Olefin containing nuclear transport modulators and uses thereof |
| AR087342A1 (es) | 2011-07-29 | 2014-03-19 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear que contienen hidrazida y sus usos |
| PE20141003A1 (es) | 2011-07-29 | 2014-09-02 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear y usos de los mismos |
| WO2013020024A2 (en) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Maleimide compounds and methods of treatment |
| NZ702663A (en) | 2012-05-09 | 2017-03-31 | Karyopharm Therapeutics Inc | Nuclear transport modulators and uses thereof |
| US20160016916A1 (en) | 2013-03-15 | 2016-01-21 | Karyopharm Therapeutics Inc. | Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof |
| US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
| WO2014205393A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| MX365939B (es) | 2013-06-21 | 2019-06-19 | Karyopharm Therapeutics Inc | Moduladores del transporte nuclear y usos de los mismos. |
| US11567063B2 (en) | 2013-11-15 | 2023-01-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods for assessing cell viability or predicting cell response to a treatment using cell movement |
| WO2016015598A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| EP3180331B1 (en) | 2014-08-15 | 2022-06-08 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| MA43530A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
| WO2017118940A1 (en) | 2016-01-08 | 2017-07-13 | Dr. Reddy's Laboratories Limited | Solid forms of selinexor and process for their preparation |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| US10993943B2 (en) | 2017-01-05 | 2021-05-04 | Watson Laboratories Inc. | Crystalline forms of selinexor and process for their preparation |
-
2013
- 2013-05-09 NZ NZ702663A patent/NZ702663A/en unknown
- 2013-05-09 ME MEP-2020-110A patent/ME03795B/me unknown
- 2013-05-09 AU AU2013259384A patent/AU2013259384B2/en active Active
- 2013-05-09 EP EP18164757.9A patent/EP3404027B1/en active Active
- 2013-05-09 JP JP2015511713A patent/JP6195909B2/ja active Active
- 2013-05-09 EP EP13779943.3A patent/EP2858991B1/en active Active
- 2013-05-09 US US13/891,044 patent/US9096543B2/en active Active
- 2013-05-09 PL PL18164757T patent/PL3404027T3/pl unknown
- 2013-05-09 KR KR1020147034556A patent/KR102095429B1/ko active Active
- 2013-05-09 US US14/399,868 patent/US9266843B2/en active Active
- 2013-05-09 KR KR1020207028485A patent/KR102223028B1/ko active Active
- 2013-05-09 MX MX2014013551A patent/MX364992B/es active IP Right Grant
- 2013-05-09 SG SG11201407268SA patent/SG11201407268SA/en unknown
- 2013-05-09 PL PL13779943T patent/PL2858991T3/pl unknown
- 2013-05-09 CA CA2872190A patent/CA2872190C/en active Active
- 2013-05-09 ES ES18164757T patent/ES2794866T3/es active Active
- 2013-05-09 LT LTEP13779943.3T patent/LT2858991T/lt unknown
- 2013-05-09 EP EP20153455.9A patent/EP3663291B1/en active Active
- 2013-05-09 UA UAA201413015A patent/UA118085C2/uk unknown
- 2013-05-09 RS RS20200639A patent/RS60424B1/sr unknown
- 2013-05-09 SM SM20200347T patent/SMT202000347T1/it unknown
- 2013-05-09 IN IN9434DEN2014 patent/IN2014DN09434A/en unknown
- 2013-05-09 HU HUE13779943A patent/HUE040427T2/hu unknown
- 2013-05-09 ES ES20153455T patent/ES3016982T3/es active Active
- 2013-05-09 SI SI201331730T patent/SI3404027T1/sl unknown
- 2013-05-09 SI SI201331239T patent/SI2858991T1/sl unknown
- 2013-05-09 RS RS20181360A patent/RS58058B1/sr unknown
- 2013-05-09 EA EA201492050A patent/EA036639B1/ru unknown
- 2013-05-09 WO PCT/US2013/040404 patent/WO2013170068A2/en active Application Filing
- 2013-05-09 CN CN201380036570.XA patent/CN104428295B/zh active Active
- 2013-05-09 PT PT181647579T patent/PT3404027T/pt unknown
- 2013-05-09 BR BR112014027860A patent/BR112014027860B8/pt active IP Right Grant
- 2013-05-09 DK DK13779943.3T patent/DK2858991T3/en active
- 2013-05-09 PE PE2014001997A patent/PE20150128A1/es active IP Right Grant
- 2013-05-09 LT LTEP18164757.9T patent/LT3404027T/lt unknown
- 2013-05-09 DK DK18164757.9T patent/DK3404027T3/da active
- 2013-05-09 ES ES13779943T patent/ES2702279T3/es active Active
- 2013-05-09 GE GEAP201313653A patent/GEP20237477B/en unknown
- 2013-05-09 UA UAA201710733A patent/UA124922C2/uk unknown
- 2013-05-09 KR KR1020207028180A patent/KR20200115688A/ko not_active Ceased
- 2013-05-09 PT PT13779943T patent/PT2858991T/pt unknown
- 2013-05-09 KR KR1020207008661A patent/KR102165177B1/ko active Active
- 2013-05-09 HU HUE18164757A patent/HUE050452T2/hu unknown
- 2013-05-09 KR KR1020207008665A patent/KR102163377B1/ko active Active
- 2013-05-09 HR HRP20181838TT patent/HRP20181838T1/hr unknown
- 2013-05-09 SM SM20180686T patent/SMT201800686T1/it unknown
-
2014
- 2014-11-10 CL CL2014003054A patent/CL2014003054A1/es unknown
- 2014-11-21 CO CO14256418A patent/CO7190242A2/es unknown
-
2015
- 2015-06-23 US US14/747,394 patent/US9861614B2/en active Active
-
2016
- 2016-01-06 US US14/989,377 patent/US9585874B2/en active Active
- 2016-09-01 AU AU2016222459A patent/AU2016222459A1/en not_active Abandoned
-
2017
- 2017-01-24 US US15/413,889 patent/US10058535B2/en active Active
- 2017-08-23 JP JP2017160341A patent/JP2018012715A/ja not_active Withdrawn
- 2017-12-04 US US15/831,048 patent/US10335393B2/en active Active
-
2018
- 2018-02-12 AU AU2018201012A patent/AU2018201012B2/en active Active
- 2018-07-17 US US16/037,798 patent/US10617677B2/en active Active
- 2018-08-20 JP JP2018154275A patent/JP2018172444A/ja not_active Withdrawn
- 2018-11-08 CY CY181101176T patent/CY1120832T1/el unknown
-
2019
- 2019-05-16 US US16/414,479 patent/US10722497B2/en active Active
- 2019-11-15 JP JP2019206852A patent/JP6818849B2/ja active Active
- 2019-11-28 AU AU2019272017A patent/AU2019272017B2/en active Active
-
2020
- 2020-04-06 US US16/840,841 patent/US10925859B2/en active Active
- 2020-06-02 HR HRP20200876TT patent/HRP20200876T1/hr unknown
- 2020-06-02 CY CY20201100517T patent/CY1123476T1/el unknown
- 2020-08-07 ZA ZA2020/04892A patent/ZA202004892B/en unknown
- 2020-12-28 JP JP2020218700A patent/JP2021063104A/ja not_active Withdrawn
-
2021
- 2021-02-19 US US17/179,512 patent/US11318120B2/en active Active
- 2021-08-23 AU AU2021221398A patent/AU2021221398B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004892B (en) | Nuclear transport modulators and uses thereof | |
| IL261612A (en) | Nuclear transfer modulators and their uses | |
| SG10201609097PA (en) | Nuclear transport modulators and uses thereof | |
| GB2509400B (en) | Rigid-stem lead-in-method and system | |
| SG11201406290QA (en) | Pallet and pallet system | |
| ZA201401223B (en) | Hydrazide containing nuclear transport modulators and uses thereof | |
| IL235826A0 (en) | Diazaspirocycloalkane and azaspirocycloalkane | |
| EP2934342A4 (en) | DEVICES AND METHODS OF DISCECTOMY | |
| EP2665362A4 (en) | NUCLEAR TRANSPORTER MODULATORS CONTAINING OLEFINS AND USES THEREOF | |
| EP2844247A4 (en) | ROR MODULATORS AND ITS USES | |
| PL2904124T3 (pl) | Urządzenie manipulacyjne | |
| EP2844259A4 (en) | MMR MODULATORS AND USES THEREOF | |
| EP2844260A4 (en) | ROR MODULATORS AND ITS USES | |
| SG11201504482VA (en) | Beta-hexosyl-transferases and uses thereof | |
| EP2874915A4 (en) | MODIFYABLE CONTAINERS AND CONNECTING ELEMENTS | |
| PL2884837T3 (pl) | Usprawnienia w urządzeniach do obsługi zwierząt | |
| GB201222541D0 (en) | Kiddibidet and pottibidet | |
| IL218974A0 (en) | Conaction bitwen coutch and playels | |
| GB201202021D0 (en) | Co-sleeper and breastfeeder | |
| GB201214019D0 (en) | SP4 and container |